drugset / Trial / NCT05048498
Pharmacokinetics, Tolerability and Safety of NEX-18a
Non-randomizedSequentialOpen-labelTreatment
Summary
The study will evaluate the safety, tolerability and pharmacokinetics of NEX-18a, a long-acting injectable azacitidine, in patients diagnosed with intermediate 2 or higher-risk MDS, CMML, or AML and already on treatment with azacitidine.
Timeline
- Start
- 2021-04-27
- Primary completion
- 2022-02-10
- Completion
- 2022-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Comparator | Azacitidine | Other / unclassified | 100 mg/m2 | Subcutaneous |
| Subject | NEX-18a | Unknown | — | Subcutaneous |